Ovarian cancer
Adoptive therapy opening new possibilities even when chemotherapy standards are exhausted.
About the disease
The main challenge in ovarian cancer is recurrence and resistance to chemotherapy. The tumor often responds to the first course of platinum drugs but stops reacting to them over time. This form is called platinum-resistant, and treatment options for it are limited. Immunotherapy adds another lever here.
We use adoptive cell therapy: we take the patient's immune cells, activate them against the tumor outside the body, and return them. These cells recognize tumor antigens and attack cells that escaped chemotherapy.
The method is used in recurrences, in platinum resistance, and in complex clinical situations where standard regimens are exhausted. Immunotherapy is built into the overall treatment plan rather than set against it.
The body's own cells work precisely and do not cause the toxicity of heavy chemotherapy. This matters for women who have already gone through several courses of treatment, when the body's reserves are limited.
The physician decides whether immunotherapy is possible and how it is structured. They assess the tumor's histology, platinum sensitivity, the number of prior treatment lines, and current condition. This determines whether the method is used on its own or as part of a combination.
When chemotherapy stops working
Works when the tumor no longer responds to platinum drugs.
Recurrence control
Immune cells look for tumor cells that escaped treatment.
Gentle tolerability
Less toxicity after several courses of chemotherapy.
Part of a comprehensive plan
Combines with surgery and drug therapy.
Tailored to tumor sensitivity
The regimen is built around histology and platinum response.
Extracorporeal immunotherapy
We move the immune 'training' process outside the body (ex vivo) — to an environment where we can create the conditions for training immunocompetent cells without creating any risk to your body.
Procedure
We draw your venous blood (up to 90 ml).
Activation (18 hours)
In the laboratory, using our proprietary technology (patents in Russia, the US, and the EU), we incubate the cells with immunomodulatory drugs and xenogeneic antigens. The cells receive a precise target.
Strike
We return the trained cells via subcutaneous injections. A powerful, multi-component immune response is developed.
Consolidation
The maintenance course forms long-term immunological memory, protecting against relapses for years.
Frequently asked questions
Does immunotherapy help when ovarian cancer is resistant to chemotherapy?
Yes, this is one of the key indications. In the platinum-resistant form the tumor does not respond to standard drugs, and activated immune cells become an additional way to act on it.
What is adoptive cell therapy?
It is a method in which the patient's immune cells are activated against the tumor outside the body and then returned. These cells are prepared in advance to recognize tumor antigens.
When is the method most appropriate?
In recurrences, in platinum resistance, and in complex situations where standard regimens have already been used. The physician decides after assessing histology and treatment history.
How is the treatment tolerated?
More gently than classic chemotherapy. The body's own cells do the work, so the method suits even women who have already gone through several courses of treatment.
Can immunotherapy be combined with surgery?
Yes. The method is built into the overall treatment plan and combined with surgery and drug therapy to strengthen control over the disease.
Can I come for treatment from another region?
Yes. The clinic is near Moscow (Khimki, Skhodnya) and accepts patients from other regions. The first consultation with a review of records can be held remotely.
Other directions
Discuss your situation
Leave your contact details. Our medical coordinator will contact you shortly to answer any questions.